Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 83 | EYES2022 | Next issue

ESE Young Endocrinologists and Scientists (EYES) 2022

Zagreb, Croatia
02 Sep 2022 - 04 Sep 2022

Card image cap

ea0083pno1 | Pituitary and Neuroendocrinology | EYES2022

Leukocyte telomere length and neuregulin-4 levels in female patients with acromegaly: Relationship between disease activation and body fat distribution

M Coskun , A. E. Altinova , A Babayeva , A. T. Sel , D Yapar , M Karaca , M. M. Yalcin , M Akturk , F Balos Toruner , I Yetkin

Background and Objectives: Leukocyte telomere length (LTL) is considered as a marker of cellular aging. Brown adipose tissue in women has been claimed to be associated with long life in women. Neuregulin-4 is a new batokine secreted from brown adipose tissue, and it is thought to play a role in the regulation of glucose, lipid metabolism and energy balance. The aim of the study is to examine LTL and serum Neuregulin-4 levels as well as their relations with disease activity, co...

ea0083pno2 | Pituitary and Neuroendocrinology | EYES2022

Real-world use of intravenous hypertonic saline for hyponatraemia: a data-driven refinement of ESE guidelines

M. F. Arshad , A. Iqbal , J Weeks , A Munir , W Bennet

Background: The European Society of Endocrinology (ESE) published guidelines to standardise intravenous hypertonic saline (HTS) for severe symptomatic hyponatraemia in 2014. Two 150 mL boluses of 3.0% HTS are proposed, one after the other, to achieve an initial sodium rise of 5 mmol/l without waiting for an interval sodium result. ESE guidelines were adopted by our University Hospital in 2017. However, high rates of sodium overcorrection were observed, and the guidelines lacke...

ea0083pno3 | Pituitary and Neuroendocrinology | EYES2022

Development of novel immunoassays for the pro-opiomelanocortin joining peptide (A surrogate marker of adrenocorticotrophin levels) for use in the diagnosis of Cushing’s syndrome

M. Donnelly

Background: Excess adrenocorticotrophin (ACTH), most often from a pituitary tumour, results in the overproduction of cortisol and the condition, Cushing’s syndrome. Plasma ACTH measurements are used in the diagnosis of Cushing’s syndrome but due to the presence of multiple dibasic cleavage sites within its sequence, ACTH is extremely labile and far from an ideal analyte. Processing of ACTH by some ectopic tumours releases high levels of smaller-ACTH like fragments, &...

ea0083pno4 | Pituitary and Neuroendocrinology | EYES2022

Cardiovascular parameters and endothelial dysfunction in Cushing’s Syndrome following remission: A prospective study

A Hacioglu , A Sezgin Caglar , S. T. Firat , Z Karaca , N Kalay , S Taheri , A Selcuklu , K Unluhizarci , F Kelestimur

Background: Cushing’s syndrome is a well-known risk factor for endothelial dysfunction, cardiovascular morbidity and mortality.Objectives: We aimed to prospectively investigate changes in metabolic and cardiovascular parameters and their correlations with markers of endothelial function in patients with endogenous Cushing syndrome following remission. Methods: Adult patients newly diagnosed with endogenous Cushing’s Syndr...

ea0083pno5 | Pituitary and Neuroendocrinology | EYES2022

Postoperative basal cortisol level as an indicator of pituitary surgery success in Cushing’s disease treatment: a single centre retrospective study

I. D. Vodanovic , A Balasko , I. Kraljevic , A Barac Nekic , T. Dusek , D. Kastelan

Background: Pituitary surgery is the primary therapy for Cushing’s disease (CD). Basal cortisol level (BCL) is measured postoperatively to evaluate the immediate efficacy of surgical treatment, but no definitive cut-off value has yet been determined as reliable. Our pituitary-dedicated centre uses an arbitrary BCL less than 50 nmol/l as expected early remission marker, identifying all patients with higher BCL as a risk group for early surgical failure.<p class="abstex...

ea0083pno6 | Pituitary and Neuroendocrinology | EYES2022

Long-term outcomes of treatment of Cushing disease in UHC Zagreb

M Raseta , M Solak , I. Kraljevic

Introduction: Cushing disease (CD) is the leading cause of endogenous hypercortisolism, caused by a pituitary tumor that produces ACTH. Treatment modalities include transsphenoidal selective adenomectomy (TSA), pharmacological therapy, radiotherapy (RT), and bilateral adrenalectomy (BA). The goal of our study was to analyze the outcomes of Cushing disease treatment in UHC Zagreb.Method: This retrospective study comprised 64 patients with CD (51 (80% wome...

ea0083pnp1 | Pituitary and Neuroendocrinology | EYES2022

Newly diagnosed diabetes mellitus in an untreated hypopituitary patient

I Cirstoc , A. I. Georgescu , I. F. Baciu , I Grigore , A Dumitrascu , C Poiana

Congenital hypopituitarism is a rare disease, occurring sporadically in the vast majority of cases, that is found more frequently in males. We are presenting the case of a 19 year old that addressed our clinic because of short stature and lack of development of secondary sexual traits. During the clinical assessment we found his height to be 146 cm, corresponding to -4.78 SDs, Tanner stage of pubertal development 1 and lack of apocrine axillary odor. The patient was inapetent ...

ea0083pnp2 | Pituitary and Neuroendocrinology | EYES2022

An unusual cause of hypopituitarism with An even more unusual presentation – a case report

K Stepanovic , T Icin , I Bajkin , M Manojlovic , M Lekin

Background: Hypopituitarism is a rare clinical condition which can present as partial or complete absence of pituitary hormones. The most common cause is a sellar or parasellar mass, particularly tumour, and the golden standard for differential diagnosis is magnetic resonance imaging. Intrasellar aneurysm is an unusual cause of hypopituitarism with an estimated incidence of 0,17% of cases.Case presentation: We report a case of a 72-year-old male who was ...

ea0083pnp3 | Pituitary and Neuroendocrinology | EYES2022

A patient with aggressive prolactinoma

T Cindric , I Kraljevic

Prolactinomas are the most common secreting pituitary tumors. Although most respond well to dopamine agonists, some prolactinomas are dopamine-resistant and very aggressive. Here we present a 37-year-old patient with aggressive prolactinoma.Case report: The 37-year-old patient was referred to the University Hospital Centre Zagreb in March 2020 for bilateral visual field defects and headaches due to prolactinoma. In 2017, he had a transsphenoidal resectio...

ea0083pnp4 | Pituitary and Neuroendocrinology | EYES2022

Hypoglicaemia in patient with unrecognized pituitary stalk interruption syndrome

T Dojcinovic , J Malinovic Pancic

Introduction: Pituitary stalk interruption syndrome (PSIS) is a rare congenital pituitary malformation characterized by the classical triad: pituitary stalk rupture, absent or ectopic neurohypophysis, and hypoplasia or aplasia of adenohypophysis. The clinical presentation depends on the age of the patient at the time of diagnosis. Patients may also have seizures, hypotension, and mental retardation at presentation. He aim is to describe a patient with an unrecognized pituitary...